Rachel Dalthorp is board certified psychiatrist and founder of a reproductive psychiatry practice called Balance Women’s Health and an interventional clinic providing ketamine and esketamine treatments.
Rachel earned her medical degree from the University of Oklahoma Health Sciences Center followed by a 4-year psychiatric residency in which she focused on gaining expertise in the treatment of women with hormone related mood disorders and sexual dysfunction.
She is a co-founder and past president of the International Society of Reproductive Psychiatry, a non-profit organization working to increase access to women’s specific mental healthcare through advocacy, education, and collaboration.
In 2016 she began to focus on providing ketamine treatment to patients with treatment resistant mental illness. Her knowledge of the impact of sex hormones on mental health along with clinical experience treating patients with ketamine led to observations and treatment protocols specific to the needs of women.
In 2020 Balance Women’s Health was acquired by the national behavioral health company LifeStance Health. She currently serves as Medical Director for the Central Division as well as the National Medical Lead for Ketamine and Spravato at LifeStance Health.